Posters

      An Impact Assessment of Combustible Cigarette Smoke Exposure on Organotypic Models of Bronchial Epithelial Mono-culture and Bronchial Epithelial/Fibroblast Co-culture

      Iskandar, A.; Xiang, Y.; Frentzel, S.; Mathis, C.; Leroy, P.; Majeed, S.; Kuehn, D.; Martin, F.; Talikka, M.; Peitsch, M.; Hoeng, J.

      Conference date
      Mar 22, 2015
      Conference name

      Society of Toxicology (SOT) 2015
      Link to more information
      Topic
      Summary

      Introduction: In organotypic tissue culture models, human primary bronchial epithelial cells form a pseudostratified epithelium, similar to the airway structure in vivo. Such models are cultured at airliquid interface, thus suitable for toxicity assessment of various aerosols. The complexity of the in vivo cellular response may be better captured in co-culture models, in which additional cell types, e.g. fibroblasts, were included. However, the presence of another cell type hinders the interpretation of the exposure impact on the epithelial cells. We compared the impact of a 28-minute whole combustible cigarette smoke (CS) exposure on two different organotypic bronchial models: a co-culture of the epithelial cells with fibroblasts and a mono-culture without fibroblasts.  Secreted cytokines levels in the basolateral media of both models were measured 48 hours post-exposure. Additionally, transcriptomes were generated at different post-exposure time points from the epithelial cells of the mono-culture model and from the epithelial cells scraped from the co-culture model. The transcriptomics data were further analyzed using a network-based systems biology approach. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.